China Issues New Risk Classification Rule For GMP Inspections
This article was originally published in PharmAsia News
The new risk-based regulation highlights recordkeeping and high-risk products with stricter enforcement for repeat offenders. Meanwhile, SFDA is also implementing an electronic monitoring system to improve drug safety.
You may also be interested in...
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.